PacBio price target lowered to $6.50 from $8 at Piper Sandler

Piper Sandler analyst David Westenberg lowered the firm’s price target on PacBio to $6.50 from $8 and keeps a Neutral rating on the shares following quarterly results. The firm assigns the 45% discount to the historical average multiple due to its views around a lower appetite for capital purchases.